176 related articles for article (PubMed ID: 37589925)
1. Survival benefit and impact of adjuvant therapies following FOLFOX-HAIC-based conversion therapy with unresectable hepatocellular carcinoma: a retrospective cohort study.
Pan Y; Yuan Z; Wang J; Ngai S; Hu Z; Sun L; Yang Z; Hu D; Chen M; Zhou Z; Zhang Y
J Cancer Res Clin Oncol; 2023 Nov; 149(16):14761-14774. PubMed ID: 37589925
[TBL] [Abstract][Full Text] [Related]
2. Hepatic arterial infusion chemotherapy with anti-angiogenesis agents and immune checkpoint inhibitors for unresectable hepatocellular carcinoma and meta-analysis.
Cao YZ; Zheng GL; Zhang TQ; Shao HY; Pan JY; Huang ZL; Zuo MX
World J Gastroenterol; 2024 Jan; 30(4):318-331. PubMed ID: 38313229
[TBL] [Abstract][Full Text] [Related]
3. Systemic therapy with or without transcatheter intra-arterial therapies for unresectable hepatocellular carcinoma: a real-world, multi-center study.
Pan Y; Zhu X; Liu J; Zhong J; Zhang W; Shen S; Jin R; Liu H; Ye F; Hu K; Xu D; Zhang Y; Chen Z; Xing B; Zhou L; Chen Y; Zeng Y; Liang X; Kuang M; Song T; Xiang B; Wang K; Sun H; Xu L;
Front Immunol; 2023; 14():1138355. PubMed ID: 37180173
[TBL] [Abstract][Full Text] [Related]
4. Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin Versus Transarterial Chemoembolization for Large Hepatocellular Carcinoma: A Randomized Phase III Trial.
Li QJ; He MK; Chen HW; Fang WQ; Zhou YM; Xu L; Wei W; Zhang YJ; Guo Y; Guo RP; Chen MS; Shi M
J Clin Oncol; 2022 Jan; 40(2):150-160. PubMed ID: 34648352
[TBL] [Abstract][Full Text] [Related]
5. Pembrolizumab plus lenvatinib with or without hepatic arterial infusion chemotherapy in selected populations of patients with treatment-naive unresectable hepatocellular carcinoma exhibiting PD-L1 staining: a multicenter retrospective study.
Chen S; Xu B; Wu Z; Wang P; Yu W; Liu Z; Huang X; Wu Y; Li T; Guo W
BMC Cancer; 2021 Oct; 21(1):1126. PubMed ID: 34670506
[TBL] [Abstract][Full Text] [Related]
6. Hepatic arterial infusion chemotherapy combined with anti-PD-1/PD-L1 immunotherapy and molecularly targeted agents for advanced hepatocellular carcinoma: a real world study.
Zhang W; Zhang K; Liu C; Gao W; Si T; Zou Q; Guo Z; Yang X; Li M; Liu D; Mu H; Li H; Yu H; Xing W
Front Immunol; 2023; 14():1127349. PubMed ID: 37180098
[TBL] [Abstract][Full Text] [Related]
7. Change of indocyanine green clearance ability and liver function after transcatheter intra-arterial therapies and its impact on outcomes of resectable hepatocellular carcinoma: a retrospective cohort study.
Gan YX; Yang ZL; Pan YX; Ou-Yang LY; Tang YH; Zhang YJ; Chen MS; Xu L
Int J Surg; 2024 May; 110(5):2832-2844. PubMed ID: 38363991
[TBL] [Abstract][Full Text] [Related]
8. One day versus two days of hepatic arterial infusion with oxaliplatin and fluorouracil for patients with unresectable hepatocellular carcinoma.
Lai Z; Huang Y; Wen D; Lin X; Kan A; Li Q; Wei W; Chen M; Xu L; He M; Shi M
BMC Med; 2022 Oct; 20(1):415. PubMed ID: 36310160
[TBL] [Abstract][Full Text] [Related]
9. [Analysis of the efficacy and safety of hepatic arterial infusion chemotherapy for unresectable hepatitis B-related intrahepatic cholangiocarcinoma].
He MR; Zheng ZK; Wu TQ; Chen MS; Zhou ZG
Zhonghua Wai Ke Za Zhi; 2024 Apr; 62(4):309-315. PubMed ID: 38432672
[No Abstract] [Full Text] [Related]
10. Comparison Between Portal Vein Perfusion Chemotherapy and Neoadjuvant Hepatic Arterial Infusion Chemotherapy for Resectable Intermediate to Advanced Stage Hepatocellular Carcinoma.
Pan Y; Mei J; Chen J; Zhang D; Wang J; Wang X; Yi M; Zhou Z; Zhang Y; Chen M; Guo R; Xu L
Ann Surg Oncol; 2022 Mar; 29(3):2016-2029. PubMed ID: 34637058
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of hepatic arterial infusion chemotherapy combined with transarterial embolization for unresectable hepatocellular carcinoma: A propensity score-matching cohort study.
Guo W; Gao J; Zhuang W; Wu Z; Li B; Chen S
JGH Open; 2020 Jun; 4(3):477-483. PubMed ID: 32514457
[TBL] [Abstract][Full Text] [Related]
12. Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion: A Randomized Clinical Trial.
He M; Li Q; Zou R; Shen J; Fang W; Tan G; Zhou Y; Wu X; Xu L; Wei W; Le Y; Zhou Z; Zhao M; Guo Y; Guo R; Chen M; Shi M
JAMA Oncol; 2019 Jul; 5(7):953-960. PubMed ID: 31070690
[TBL] [Abstract][Full Text] [Related]
13. Tenofovir versus Entecavir on Outcomes of Hepatitis B Virus-Related Hepatocellular Carcinoma After FOLFOX-Hepatic Arterial Infusion Chemotherapy.
Zheng Z; Wang J; Wu T; He M; Wang J; Pan Y; Chen J; Hu D; Xu L; Zhang Y; Chen M; Zhou Z
J Hepatocell Carcinoma; 2023; 10():2117-2132. PubMed ID: 38053944
[TBL] [Abstract][Full Text] [Related]
14. Induction therapy with hepatic arterial infusion chemotherapy enhances the efficacy of lenvatinib and pd1 inhibitors in treating hepatocellular carcinoma patients with portal vein tumor thrombosis.
Fu Y; Peng W; Zhang W; Yang Z; Hu Z; Pang Y; Hu D; Chen J; Wang J; Zhou Z; Xu L; Chen M; Zhang Y
J Gastroenterol; 2023 Apr; 58(4):413-424. PubMed ID: 36894804
[TBL] [Abstract][Full Text] [Related]
15. Postoperative Adjuvant Hepatic Arterial Infusion Chemotherapy With FOLFOX in Hepatocellular Carcinoma With Microvascular Invasion: A Multicenter, Phase III, Randomized Study.
Li SH; Mei J; Cheng Y; Li Q; Wang QX; Fang CK; Lei QC; Huang HK; Cao MR; Luo R; Deng JD; Jiang YC; Zhao RC; Lu LH; Zou JW; Deng M; Lin WP; Guan RG; Wen YH; Li JB; Zheng L; Guo ZX; Ling YH; Chen HW; Zhong C; Wei W; Guo RP
J Clin Oncol; 2023 Apr; 41(10):1898-1908. PubMed ID: 36525610
[TBL] [Abstract][Full Text] [Related]
16. Survival benefit of preoperative hepatic arterial infusion of oxaliplatin, fluorouracil, and leucovorin followed by hepatectomy for hepatocellular carcinoma.
Hu Z; Yang Z; Pan Y; Fu Y; Wang J; Zhou Z; Chen M; Hu D; Zhang Y
Front Pharmacol; 2023; 14():1210835. PubMed ID: 37456741
[No Abstract] [Full Text] [Related]
17. Hepatic artery infusion chemotherapy using mFOLFOX versus transarterial chemoembolization for massive unresectable hepatocellular carcinoma: a prospective non-randomized study.
He MK; Le Y; Li QJ; Yu ZS; Li SH; Wei W; Guo RP; Shi M
Chin J Cancer; 2017 Oct; 36(1):83. PubMed ID: 29061175
[TBL] [Abstract][Full Text] [Related]
18. Comparison of hepatic arterial infusion chemotherapy versus sorafenib monotherapy in patients with advanced hepatocellular carcinoma.
Kawaoka T; Aikata H; Hyogo H; Morio R; Morio K; Hatooka M; Fukuhara T; Kobayashi T; Naeshiro N; Miyaki D; Hiramatsu A; Imamura M; Kawakami Y; Takahashi S; Waki K; Tsuji K; Kohno H; Kohno H; Moriya T; Chayama K
J Dig Dis; 2015 Sep; 16(9):505-12. PubMed ID: 26121102
[TBL] [Abstract][Full Text] [Related]
19. Treatment efficacy by hepatic arterial infusion chemotherapy vs. sorafenib after liver-directed concurrent chemoradiotherapy for advanced hepatocellular carcinoma.
Han S; Choi HJ; Beom SH; Kim HR; Lee H; Lee JS; Lee HW; Park JY; Kim SU; Kim DY; Ahn SH; Han KH; Seong J; Won JY; Kim BK
J Cancer Res Clin Oncol; 2021 Oct; 147(10):3123-3133. PubMed ID: 33893539
[TBL] [Abstract][Full Text] [Related]
20. Adjuvant hepatic arterial infusion chemotherapy is beneficial for selective patients with Hepatocellular carcinoma undergoing surgical treatment.
Hsiao JH; Tsai CC; Liang TJ; Chiang CL; Liang HL; Chen IS; Chen YC; Chang PM; Chou NH; Wang BW
Int J Surg; 2017 Sep; 45():35-41. PubMed ID: 28728985
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]